Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools

by Sean Ekins
Sold out
Current price ₹10,529.00
Original price ₹16,198.00
Original price ₹16,198.00
Original price ₹16,198.00
(-35%)
₹10,529.00
Current price ₹10,529.00

Imported Edition - Ships in 18-21 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Hardcover
  • ISBN13: 9780470225554
  • Binding: Hardcover
  • Subject: N/A
  • Publisher: Wiley
  • Publisher Imprint: Wiley
  • Publication Date:
  • Pages: 424
  • Original Price: USD 171.95
  • Language: English
  • Edition: N/A
  • Item Weight: 708 grams
  • BISAC Subject(s): Pharmacology and Pharmacy

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools covers key emerging technologies in pharmaceutical R & D and how they have substantially impacted (or are currently impacting) drug discovery. The cross-disciplinary collaborations implicit in integrating these technologies with drug discovery operations will fuel the engine for future innovations. This book cuts across the multiple areas of drug discovery, each chapter authored by pioneers in that field, making for a broad appeal to the chemical and biological scientists and technologists involved in drug discovery and development.

Sean Ekins, MSc, PHD, DSc, is the Principal at Collaborations in Chemistry; and Adjunct Associate Professor in the Department of Pharmaceutical Sciences at the University of Maryland, School of Pharmacy. Dr. Ekins has published widely on ADME/Tox, systems biology, computational, and in vitro drug discovery approaches. He has previously edited two Wiley books: Computer Applications in Pharmaceutical Research and Development (2006) and Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals (2007).

Jinghai J. Xu, PHD, is Director of Automated Biotechnology at Merck. Previously he headed predictive toxicology at Pfizer, where he led research activities in drug-induced liver injury, genetic toxicology, drug transporters, assay development, high content screening, in vitro in vivo correlations, systems biology, and systems toxicology. Dr. Xu has served on steering committees of academic-industry and industry-industry collaborations, and as a guest lecturer at the Massachusetts Institute of Technology.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us